Boston Scientific Corporation's 2026 Annual Meeting resulted in the election of 10 directors and the approval of charter amendments to eliminate supermajority voting provisions and provide for officer exculpation. Shareholders also approved an increase in shares for the Employee Stock Purchase Plan but rejected a proposal that would have allowed stockholders owning at least 25% of common stock to call special meetings.
